SynthesisVascular health and risk management2010
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review.
Synthesis in Vascular health and risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Cerebrolysin for vascular dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Pharmacological interventions for cognitive decline in people with Down syndrome.The Cochrane database of systematic reviews · 2015Pooled it
- Trial
- Development of a mortality prediction nomogram for dementia patients using the MIMIC-IV database.Scientific reports · 2026Article
- Biomarker pathway heterogeneity of amyloid-positive individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Effects of Physical Activity on Experimental Models of Vascular Dementia: A Systematic Review and Meta-Analysis.Annals of neurosciences · 2024Review
- Baseline Profiles of Drug Prescriptions Prior to Diagnosis of Mild Cognitive Impairment (MCI) Obtained by Latent Class Analysis (LCA), and Assessment of Their Association with Conversion to Dementia.Healthcare (Basel, Switzerland) · 2023Article
- Risk factors for incidence of dementia in primary care practice: a retrospective cohort study in older adults.Family practice · 2022Article
- Review
- Design and evaluation of a cognitive health education pilot program according to the RE-AIM framework.PloS one · 2021Article
- Article
- Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study.BMC neurology · 2020Observational
- Hypertension management: experiences, wishes and concerns among older people-a qualitative study.BMJ open · 2019Article
- Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study).Contemporary clinical trials · 2019Article
- Treatable Vascular Risk and Cognitive Performance in Persons Aged 35 Years or Older: Longitudinal Study of Six Years.The journal of prevention of Alzheimer's disease · 2019Article
- Cognitive impairment and medication adherence post-stroke: A five-year follow-up of the ASPIRE-S cohort.PloS one · 2019Article
- The association between blood pressure variability (BPV) with dementia and cognitive function: a systematic review and meta-analysis protocol.Systematic reviews · 2018Article
- Association of cardiovascular system medications with cognitive function and dementia in older adults living in nursing homes in Australia.Journal of geriatric cardiology : JGC · 2017Article
- Impact of coronary heart disease on cognitive decline in Alzheimer's disease: a prospective longitudinal cohort study in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2017Article
- Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.Medicine · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
objectiveTo systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline. SELECTION CRITERIA: RCTs studying the effect of treating hypertension, dyslipidemia, hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations. OUTCOME MEASURE: Cognitive decline or incident dementia. MAIN
resultsIn the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
conclusionThe evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.